047920 — HLB Pharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapNeutral

Annual cashflow statement for HLB Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	473	-74,840	-13,226	-11,777	-19,427
Depreciation
Amortisation
Non-Cash Items	1,817	76,473	15,322	9,275	1,787
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-2,576	-4,101	-7,209	-4,796	-5,723
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	1,353	-403	-1,321	-2,763	-18,317
Capital Expenditures	-1,937	-2,981	-49,511	-2,901	-4,255
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-5,001	-53,131	33,754	-10,380	13,837
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-6,938	-56,112	-15,757	-13,281	9,582
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	5,299	67,855	9,634	19,148	3,758
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-286	11,339	-7,444	3,105	-4,978